Measurable Residual Disease (MRD) is a key prognostic marker in acute leukaemias, guiding therapy and risk stratification. Even in morphologic remission, residual clones drive relapse, highlighting the need for sensitive, standardised detection. This narrative review synthesises evidence from PubMed, Embase, and Scopus...
S. Sukumar, Samarth Shukla, S. Vagha et al.· Journal of Clinical and Diag...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.